Bide Pharmatech Soars 20% to Day High of CNY 73.92 Amid Strong Performance

Bide Pharmatech Co., Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a significant surge in its stock price, gaining 20.0% on August 10, 2026. The stock reached an intraday high of CNY 73.92, reflecting strong market activity. In terms of performance metrics, Bide Pharmatech has outperformed the China Shanghai Composite index across various time frames. Over the past day, the stock's performance stood at 20.0%, compared to the index's modest gain of 0.67%. The one-week performance is particularly noteworthy, with a remarkable increase of 59.48%, while the one-month performance shows a gain of 39.34%. Year-to-date, the stock has risen by 21.08%, contrasting with a slight decline in the broader market. Financially, Bide Pharmatech reported its highest quarterly net sales at CNY 351.58 million, alongside a decrease in raw material costs by 6.78% year-over-year. The company's return on equity stands at 6.97%, and it maintains a price-to-book ratio of 3.56, indicating a solid valuation. With a dividend yield of 0.65%, Bide Pharmatech continues to demonstrate resilience and growth potential in a competitive industry landscape.